# Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)

> **NCT02118415** · PHASE2 · COMPLETED · sponsor: **Technical University of Munich** · enrollment: 13 (actual)

## Conditions studied

- NSCLC Stage IIIA/B

## Interventions

- **OTHER:** Hsp70-peptide TKD/IL-2 activated, autologous NK cells

## Key facts

- **NCT ID:** NCT02118415
- **Lead sponsor:** Technical University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2018-03-28
- **Final completion:** 2019-03
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118415, "Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02118415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*